Which problem is being addressed?
Lip shape, midface support, under-eye concerns and jawline contour are different goals. Product class, prior filler, tissue characteristics and the option of no procedure belong in the decision.
Dermal fillers may be considered for selected volume-loss or contour goals. Anatomy, vascular risk, product class, traceability and follow-up are assessed together.
Duration
30-45 minutes
Body Location
Lips, cheeks, jawline, chin, under-eye or selected facial areas after assessment
Preparation
Avoid alcohol for 24 hours. Do not stop prescribed medication, including aspirin or anticoagulants, on your own; disclose it and coordinate any change with the prescribing clinician.
Follow-up Care
Aftercare and follow-up depend on the person and product. Increasing pain, blanching, mottled discoloration or visual symptoms require urgent assessment.
A physician places the selected filler in the planned tissue. Early appearance may be affected by swelling; assessment depends on recovery and follow-up findings.
Botulinum toxin and dermal filler are often discussed together, but they address different tissues and goals. Botulinum toxin can temporarily reduce activity in selected muscles; filler may add volume or structural support in an appropriate patient. This comparison explains general decision factors; an individual choice requires facial assessment, medical history, and examination.
| Criterion | Botox (Botulinum Toxin) | Dermal Filler (Hyaluronic Acid) |
|---|---|---|
| Primary Goal | Relaxes expression muscles to reduce dynamic wrinkles (forehead, glabellar lines, crow's feet). | Restores volume loss, fills static lines and contours (lips, cheeks, nasolabial folds). |
| Mechanism of Action | Blocks acetylcholine release to temporarily reduce muscle contraction. | Delivers hyaluronic acid to tissue; binds water between cells, adds volume and structural support. |
| Procedure Duration | 10–15 minutes | 30–45 minutes |
| Onset of Results | 3–7 days, full effect at 2 weeks | Immediately visible; settles over 1–2 weeks as swelling resolves |
| Longevity | 3–4 months | 9–18 months depending on product |
| Reversible? | Its effect fades over time; there is no standard method that immediately reverses treatment. | Some hyaluronic-acid fillers may be reduced with physician-directed hyaluronidase; the speed and extent of response vary. Suspected vascular occlusion requires urgent assessment. |
| Downtime | Return to routine is often quick; bruising, headache, or temporary asymmetry can occur. | Swelling and bruising can occur; duration varies by area, product, and individual response. |
| Findings That Guide the Choice | Lines driven by muscle movement, muscle strength, and the balance of adjacent structures. | Volume loss, contour needs, tissue quality, and vascular anatomy. |
| How Is the Fee Determined? | The muscles assessed, dose, product, and review plan are determined after physician examination. | Product type, amount, treatment area, technique, and follow-up plan are determined after physician examination. |
Dr. Gemici's Recommendation
Movement-related lines may prompt a botulinum-toxin assessment, while volume or structural-support needs may prompt a filler assessment. Some people may be considered for both approaches at different times, but age alone is not a decision rule. Suitability, expected benefit, and risks should be discussed during an in-person physician assessment.
Dermal filler decision guide
Filler choice involves anatomy, product properties, alternatives and follow-up. It should not begin with a brand ranking or a predetermined volume.
Lip shape, midface support, under-eye concerns and jawline contour are different goals. Product class, prior filler, tissue characteristics and the option of no procedure belong in the decision.
Unintentional injection into a vessel can cause tissue injury and, in some circumstances, visual loss or stroke. Increasing pain, blanching, a mottled pattern or visual symptoms require immediate assessment; do not wait for an online reply.
Ultrasound can assist assessment of anatomy or existing material. Its usefulness depends on the operator, image quality, material and clinical question. It does not eliminate vascular occlusion risk or replace urgent clinical assessment.
Swelling, nodules or inflammation can appear weeks, months or later after injection. Causes differ. Record the product and date and seek assessment; a remote description is not enough to select antibiotics, steroids or dissolving treatment.
No. Hyaluronidase acts on hyaluronic acid; it is not a universal antidote for all filler materials or complications. Product selection, consent and a plan for complications remain necessary.
People with volume loss or particular contour goals may be assessed after reviewing anatomy, prior filler, medical history and expectations. Different areas require different product and planning decisions. Choosing no procedure is also an option.
Duration varies with the product, area, treatment characteristics and individual response. A reduced visible effect does not prove that all material has disappeared. Repeat treatment is based on assessment, not a fixed schedule.
Check the exact product, manufacturer, batch, expiry date, source and current regulatory status in Turkey. A brand family or authorization in another country does not establish suitability for every product or area.
Alongside bruising, swelling and tenderness, infection, nodules, asymmetry and vascular occlusion can occur. Injection into a vessel may cause tissue injury, vision loss or stroke. Not every complication is fully reversible.
Increasing or unexpectedly severe pain, blanching, mottled discoloration or visual symptoms require urgent in-person assessment. Do not wait for a routine appointment or an online reply.
No. Ultrasound can help assess anatomy or existing material, depending on the product, image quality and operator experience. It does not guarantee that vascular occlusion cannot occur and must not delay urgent assessment.
Yes. Delayed swelling, nodules or inflammation can occur. Causes differ, so lumps do not all receive the same treatment. Share the product name and date with the assessing clinician; do not self-treat with massage, medication or dissolving injections.
No. Hyaluronidase acts on hyaluronic acid; it is not a universal solution for other filler classes or all complications. Its use requires a separate medical assessment and discussion of risks.
Volume is not selected from an age band or an online package. The area, anatomy and goals are assessed in consultation. A restrained result can be the aim, but appearance and satisfaction vary.
Elective filler is generally deferred during pregnancy and breastfeeding. Discuss allergies, infection and medication history. Do not stop prescribed medicines that may affect bleeding on your own; changes require the prescribing clinician.
Dermal Fillers is a safe procedure; still, as with any medical treatment, explaining possible side effects and rare complications transparently is part of patient safety. The physician-authored guides below cover these topics in depth.
This content is informational and does not replace medical advice. At any warning sign, contact the physician who performed the procedure or the nearest medical facility without delay.
Deep-dive in our glossary: definition, indications, side effects and FAQs.
Nasolabial filler; It is a hyaluronic acid injection that provides medial cheek support for the treatment of the deep fold (nasolabial fold) extending from the corner of the mouth to the side of the nose. With the "Lift not fill" principle, it reduces the visibility of the fold by shifting the cheek tissue above the fold upwards rather than filler the fold.
Jawline contour; An aesthetic technique that shapes the mandibular edge line (ramus, gonion, chin tip) with a combination of CaHA/HA filler and masseter Botox, providing lower facial proportions, sharp definition in men, and elegant taper in women.
These are selected peer-reviewed medical publications. Findings are limited to the studied product, device and indication; authorization and administration route require separate verification. Publication titles are retained in their original language for reliable lookup.
A randomized trial in 60 participants compares CaHA with a particular hyaluronic acid filler for nasolabial folds. The complications review describes risks including vascular occlusion; it does not establish equivalence across all fillers.
Evidence summary reviewed by Dr. Hamza Gemici · · Review log
Contact Dr. Hamza Gemici’s clinic for individualized assessment and candidacy planning.